Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 17 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

Scholar Rock Holding Corp

Market implies +71.2%/yr vs model +15.0% · above model

Strata Critical Medical, Inc.

Market implies +8.6%/yr vs model +40.6% · below model

Sensus Healthcare, Inc.

Deeply overvalued

Premium +50% Return to IV: -33.2%

Market implies +0.8%/yr vs model +2.0% · in line

Surrozen, Inc./DE

SS Innovations International, Inc.

Deeply overvalued

Premium +291% Return to IV: -74.4%

Market implies +6.9%/yr vs model +15.0% · below model

Sensata Technologies Holding plc

Deeply overvalued

Premium +59% Return to IV: -37.0%

Owner yield 6.3% 10-yr IRR 10.6% · steady

Market implies +11.2%/yr vs model +5.0% · above model

STAAR SURGICAL CO

Market implies +10.4%/yr vs model +2.0% · above model

Model IV$269.87

Discount 24% Return to IV: +31.6%

Owner yield 2.9% 10-yr IRR 6.6% · grower

Market implies +7.4%/yr vs model +13.6% · below model

Market implies +113.4%/yr vs model +15.0% · above model

Neuronetics, Inc.

Deeply undervalued

Premium +9% Return to IV: -8.3%

Market implies +2.5%/yr vs model +28.2% · below model

Stoke Therapeutics, Inc.

Deeply overvalued

Premium +195% Return to IV: -66.1%

Market implies +9.4%/yr vs model +15.0% · below model

SUTRO BIOPHARMA, INC.

Market implies -4.2%/yr vs model +13.4% · below model

Market implies +82.5%/yr vs model +15.0% · above model

Sharps Technology Inc.

Deeply overvalued

Premium +199% Return to IV: -66.6%

Market implies +12.5%/yr vs model +15.0% · in line

Shattuck Labs, Inc.

Market implies +108.7%/yr vs model +2.0% · above model

Stevanato Group S.p.A.

Stereotaxis, Inc.

Market implies +46.1%/yr vs model +2.0% · above model

SUPERNUS PHARMACEUTICALS, INC.

Deeply overvalued

Premium +44% Return to IV: -30.7%

Market implies +0.5%/yr vs model +5.5% · below model

SINOVAC BIOTECH LTD

Discount 15% Return to IV: +17.0%

Market implies -9.9%/yr vs model +2.0% · below model

China SXT Pharmaceuticals, Inc.

Market implies +20.5%/yr vs model +2.0% · above model

60 DEGREES PHARMACEUTICALS, INC.

Deeply undervalued

Discount 74% Return to IV: +280.6%

Market implies -23.4%/yr vs model +50.0% · below model

Model IV$362.38

Discount 24% Return to IV: +31.7%

Owner yield 3.4% 10-yr IRR 6.1% · moderate

Market implies +4.8%/yr vs model +10.1% · below model

SYPRIS SOLUTIONS INC

Deeply undervalued

Discount 72% Return to IV: +256.7%

Market implies -25.4%/yr vs model +5.3% · below model

Spyre Therapeutics, Inc.

Market implies +150.0%/yr vs model +15.0% · above model

TAKEDA PHARMACEUTICAL CO LTD

Talkspace, Inc.

Premium +10% Return to IV: -9.5%

Market implies -4.2%/yr vs model +19.1% · below model

Talkspace, Inc.

Market implies -50.0%/yr vs model +15.0% · below model

Protara Therapeutics, Inc.

Tarsus Pharmaceuticals, Inc.

Deeply undervalued

Model IV$116.64

Discount 32% Return to IV: +47.1%

Market implies -8.8%/yr vs model +50.0% · below model

Theravance Biopharma, Inc.

Deeply undervalued

Model IV$154.19

Discount 89% Return to IV: +806.5%

Market implies -16.8%/yr vs model +19.6% · below model

TACTILE SYSTEMS TECHNOLOGY INC

Deeply undervalued

Discount 43% Return to IV: +73.9%

Owner yield 7.2% 10-yr IRR 17.8% · moderate

Market implies +1.3%/yr vs model +11.5% · below model

Alaunos Therapeutics, Inc.

Market implies +92.7%/yr vs model +2.0% · above model

TScan Therapeutics, Inc.

Market implies +60.9%/yr vs model +2.0% · above model

Teladoc Health, Inc.

Deeply undervalued

Discount 54% Return to IV: +119.1%

Owner yield 27.9% 10-yr IRR 42.3% · moderate

Market implies -7.5%/yr vs model +6.9% · below model

BIO-TECHNE Corp

Deeply overvalued

Premium +245% Return to IV: -71.0%

Owner yield 2.0% 10-yr IRR -1.6% · moderate

Market implies +23.8%/yr vs model +7.9% · above model

Tectonic Therapeutic, Inc.

Deeply undervalued

Discount 84% Return to IV: +513.0%

Market implies -41.4%/yr vs model +28.5% · below model

Telomir Pharmaceuticals, Inc.

TENAX THERAPEUTICS, INC.

Market implies +51.1%/yr vs model +2.0% · above model

TEVA PHARMACEUTICAL INDUSTRIES LTD

Deeply overvalued

Premium +164% Return to IV: -62.1%

Owner yield 2.1% 10-yr IRR -3.6% · steady

Market implies +16.9%/yr vs model +4.5% · above model

Deeply overvalued

Premium +112% Return to IV: -52.9%

Market implies +8.1%/yr vs model +2.0% · above model

TG THERAPEUTICS, INC.

Premium +26% Return to IV: -20.6%

Market implies -0.8%/yr vs model +50.0% · below model

TENET HEALTHCARE CORP

Owner yield 7.4% 10-yr IRR 15.9% · moderate

Market implies -6.1%/yr vs model +8.6% · below model

Instil Bio, Inc.

Alpha Teknova, Inc.

Market implies +47.0%/yr vs model +2.4% · above model

Market implies +119.8%/yr vs model +2.0% · above model

Tilray Brands, Inc.

Market implies +29.1%/yr vs model +12.5% · above model

Tiziana Life Sciences Ltd

TriSalus Life Sciences, Inc.

Deeply overvalued

Premium +207% Return to IV: -67.5%

Market implies +11.4%/yr vs model +15.0% · below model

TriSalus Life Sciences, Inc.

Deeply undervalued

Discount 77% Return to IV: +327.0%

Market implies -24.2%/yr vs model +50.0% · below model

Telix Pharmaceuticals Ltd

TREACE MEDICAL CONCEPTS, INC.

Deeply overvalued

Premium +70% Return to IV: -41.0%

Market implies +9.7%/yr vs model +22.5% · below model

TransMedics Group, Inc.

Deeply overvalued

Premium +97% Return to IV: -49.2%

Market implies +17.6%/yr vs model +10.0% · above model

THERMO FISHER SCIENTIFIC INC.

Deeply overvalued

Model IV$308.01

Premium +112% Return to IV: -52.7%

Owner yield 2.8% 10-yr IRR 0.9% · moderate

Market implies +15.3%/yr vs model +6.5% · above model

TANDEM DIABETES CARE INC

Discount 2% Return to IV: +2.2%

Market implies -1.7%/yr vs model +9.6% · below model

Tango Therapeutics, Inc.

Market implies +46.9%/yr vs model +13.9% · above model

Tenon Medical, Inc.

Tonix Pharmaceuticals Holding Corp.

Market implies +47.7%/yr vs model +15.0% · above model